Axsome Therapeutics, Inc. Stock News

Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation

Shares of biopharmaceutical company Axsome Therapeutics (AXSM -6.29%) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol (brand name Sunosi) in major depressive disorder (MDD).

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive. The post Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week appeared first on Investor's Business Daily.

Axsome Therapeutics said on Tuesday its experimental drug to treat major depressive disorder failed to meet the main goal of a late-stage study.

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded down a wide variety of stocks in both fields.

Axsome Therapeutics said on Tuesday its experimental drug to treat attention deficit hyperactivity disorder (ADHD) met the main goal in a late-stage study.

Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions in multiple Phase 3 trials. The FDA has greenlit Axsome to submit an sNDA for AXS-05 without requiring new trials, based on robust existing data. AXS-05 demonstrates a favorable safety profile with low discontinuation rates due to adverse events, unlike competitors such as AVP...

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering